Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
APMD
vs
S&P 500
S&P 500
Over the past 12 months, APMD has underperformed S&P 500, delivering a return of +14% compared to S&P 500's +17% growth.
Stocks Performance
APMD vs S&P 500
Performance Gap
APMD vs S&P 500
Performance By Year
APMD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Apnimed Inc
Glance View
Apnimed Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2026-07-31. Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The firm's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.